Data Foundry

Drug recalls 2023

Oxybutynin Chloride Extended-Release Tablets USP 10 mg — Class II drug recall D-0038-2024

Terminated recall by Zydus Pharmaceuticals (USA) Inc, reported 2023-10-11, distributed nationwide. Failed Dissolution Specifications

Recall numberD-0038-2024
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmZydus Pharmaceuticals (USA) Inc, Pennington, NJ, United States
Recall initiated2023-09-21
Classified2023-10-04
Reported by FDA2023-10-11
Terminated2025-08-06
DistributedNationwide (US)
Quantity7,248 bottles
Reason classesspecification failure
NDC68382-0255, 68382-0255-01, 68382-0255-05, 68382-0255-06, 68382-0255-14, 68382-0255-16, 68382-0255-30, 68382-0255-77, 68382-0256, 68382-0256-01, 68382-0256-05, 68382-0256-06, 68382-0256-14, 68382-0256-16, 68382-0256-30, 68382-0256-77, 68382-0257, 68382-0257-01, 68382-0257-05, 68382-0257-06, 68382-0257-14, 68382-0257-16, 68382-0257-30, 68382-0257-77
Lot numbersM300651, M300652
Expiration dates2024-12-20

Product

Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534

Reason for recall

Failed Dissolution Specifications

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0038-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.